Health Bulletin 5/April/2023

Published On 2023-04-05 12:04 GMT   |   Update On 2023-04-06 10:45 GMT
Advertisement

Here are the top health stories for the day:


People need to remain vigilant against new COVID strain: Official


Rajasthan doctors call off strike on RTH Bill after govt agreement

Putting an end to the ongoing feud between doctors and the State Government of Rajasthan regarding the implementation of Right to Health Bill, the State has now agreed to the demands by the protesting doctors regarding the rules under recently passed bills.

Advertisement

With the new agreement between the State and the doctors, the strike by the private doctors in Rajasthan in the form of a complete medical shutdown has been called off.

For more details, check out the link given below:

Rajasthan Doctors Call Off Strike On RTH Bill After Govt Agreement


Johnson & Johnson proposes $8.9 bn settlement for talc cancer claims

US pharmaceutical giant Johnson & Johnson on Tuesday proposed an $8.9 billion settlement to resolve years-old lawsuits claiming that its talcum powder products caused cancer.

The New Jersey-based company said the proposed settlement, which still needs the approval of a bankruptcy court, "will equitably and efficiently resolve all claims arising from cosmetic talc litigation."

For more details, check out the link given below:

JnJ proposes USD 8.9 billion settlement of talc cancer claims


US CDC flags concern over use of Global Pharma Healthcare eye drop

The US Centers for Disease Control and Prevention (CDC) has flagged concern over the use of an Indian eye drop that is causing death and blindness among its citizens.

However, the Tamil Nadu Drugs Control said there is no contamination, according to media reports.

The CDC has, in recent months, traced three deaths, eight cases of blindness and dozens of infections caused by a highly drug-resistant bacteria linked to Chennai-based EzriCare artificial tears, made by Global Pharma Healthcare, The New York Times reported.

For more details, check out the link given below:

US CDC Flags Concern Over Use Of Global Pharma Healthcare Eye Drop

Max Super Speciality Hospital absolved of medical negligence, told to pay Rs 1 lakh compensation for administrative lapses

The National Consumer Disputes Redressal Commission (NCDRC) has absolved Max Super Speciality Hospital, Patparganj, Delhi of medical negligence, however, it ordered the facility to pay Rs 1 lakh compensation for administrative lapse to the patient who alleged failure to detect presence of Schistocytes in Peripheral Blood Smear (PBS), which resulted in delayed diagnosis of Micro-Angiopathic Hemolytic Anaemia (MAHA) and its treatment.

Presiding Member of NCDRC, Dr SM Kantikar strictly cautioned and directed the hospital to take necessary steps for systemic improvement.

For more details, check out the link given below:

Max Super Speciality Hospital Absolved Of Medical Negligence, Told To Pay Rs 1 Lakh Compensation For Administrative Lapses

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News